This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-04 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Competition with analogs For releasing the His-tagged protein from the carrier, a compound is used that has a structure similar to the His-tag and which also forms a coordination complex with the immobilized metal ions. Such a compound added to the His-tagged protein on the carrier competes with the protein for the immobilized metal ions. The compound added at high concentration replaces virtually all carrier-bound protein which is thus eluted from the carrier. Imidazole is the side chain of histidine and is typically used at a concentration of 100 - 500 mM for elution. Histidine can also be used.
=== Bayliss and Starling (1902) === William Bayliss and Ernest Starling, a physiologist and biologist respectively, wanted to see if the nervous system had an impact on the digestive system. From the work of Martin Heidenhain and Claude Bernard, they knew that the pancreas was involved in the secretion of digestive fluids after the passage of food from the stomach to the intestines, which they believed to be due to the nervous system. They cut the nerves to the pancreas in an animal model and discovered that it was not nerve impulses that controlled secretion from the pancreas. It was determined that a factor secreted from the intestines into the bloodstream was stimulating the pancreas to secrete digestive fluids. This was named secretin: a hormone. In 1905, Starling coined the word hormone from the Greek to arouse or excite which he defined as "the chemical messengers which speeding from cell to cell along the blood stream, may coordinate the activities and growth of different parts of the body".
Some childhood memories made lifelong impressions on him. As a boy, he carved a tiny mannequin into the end of the wooden ruler from his pencil case and placed it inside it. He added a stone, which he had painted into the upper and lower halves, and hid the case in the attic. Periodically, he would return to the mannequin, often bringing tiny sheets of paper with messages inscribed on them in his own secret language. He later reflected that this ceremonial act brought him a feeling of inner peace and security. Years later, he discovered similarities between his personal experience and the practices associated with totems in Indigenous cultures, such as the collection of soul-stones near Arlesheim or the tjurungas of Australia. He concluded that his intuitive ceremonial act was an unconscious ritual, which he had practiced in a way that was strikingly similar to those in distant locations which he, as a young boy, knew nothing about. His observations about symbols, archetypes, and the collective unconscious were inspired, in part, by these early experiences combined with his later research. At the age of 12, shortly before the end of his first year at the Humanistisches Gymnasium in Basel, Jung was pushed to the ground by another boy and hit his head, momentarily losing consciousness (he later recognised the incident was indirectly his fault). A thought then came to him—"Now you won't have to go to school anymore". From then on, whenever he walked to school or began homework, he fainted.
The step of salting the raw materials as well as the addition of red pepper powder inhibits the pathogenic and putrefactive bacteria present in the microflora, allowing the lactic acid bacteria (LAB) to flourish and become the dominant microorganism. These anaerobic microorganisms steadily increase in number during the middle stages of fermentation, and prefer to be kept at low temperatures of about 10 °C, pH of 4.2-4, and remain in the presence of 1.5% – 4% NaCl. A faster fermentation at a higher temperature may be chosen as well to accelerate the growth of bacterial cultures for a faster decrease in pH level. Since the raw cruciferous vegetables themselves are the source of LAB required for fermentation, no starter culture is required for the production of kimchi; rather, spontaneous fermentation occurs. The total population of microorganisms present at the beginning of processing determines the outcome of fermentation, causing the final product to be highly variable in terms of quality and flavor. Currently, there are no recommended approaches to control the microbial community during fermentation to predict the outcome. In the industrial production of kimchi, starter cultures made up of Leu. mesenteroides, Leu. citreum, and Lb. plantarum are used, which are often unsuccessful because they fail to outcompete the naturally occurring cultures on the raw materials.
Sources: en.wikipedia.org
White Castle also markets its sandwiches in 20 or 30-hamburger boxes, called a Crave Clutch or Crave Case, respectively. The figure of 30 burgers represents the number that can be produced on one of its standard griddles at the same time. A "Crave Crate" is also offered, with the contents being 100 burgers. To celebrate its 100th year in operation, White Castle re-introduced their original burger, called the 1921 Slider. It features an addition of lettuce, tomato, and caramelized onions. Typically normal sliders have 5 holes in the patty while cooking on a griddle of onions and water to steam the sliders to completion. The 1921 is grilled directly on the griddle instead. A variety of White Castle products (mostly frozen) are also sold in grocery stores. Some locations had been cobranded with Church's Chicken until that co-branding arrangement ended around 2010. Around 2012, White Castle experimented with the Laughing Noodle brand that was to share space with White Castle restaurants. The Laughing Noodle concept was discarded a few years later. The Laughing Noodle brand was developed to offer supplemental variety to a White Castle Restaurant. At least one such location was constructed and operated in Sharonville, Ohio. Although White Castle originated in Wichita, Kansas, the city has not had a restaurant since 1938, nor is there a White Castle restaurant in the entire state of Kansas. White Castle is one of the few restaurant chains that does not have a location in its original city.
== Professional career == Following her graduation in 1958, Susan Leeman was offered a one-year position as an instructor in the Physiology Department at Harvard Medical School. Realizing she was only a fill-in, the following year she took a job at Brandeis University where she stayed for the next 12 years. During this time she received a Career Development Award which helped her to balance her career and family life. Leeman's research while at Brandeis University mainly focused on the effect a corticotropin-releasing factor (CRF) had on the secretion of adrenocorticotrophic hormone (ACTH) from the anterior pituitary gland. During her effort to purify the CRF, she discovered a peptide that could stimulate the secretion of saliva. This caused her to switch the direction of the project entirely, as she decided to further investigate this peptide. Eventually Leeman and her lab realized she had unintentionally isolated substance P – a peptide originally discovered by Ulf von Euler in the 1930s, but had yet to be chemically defined. Leeman went on to discover the amino acid sequence of substance P and published her findings in the Journal of Biological Chemistry in 1970. During the purification process of substance P, Leeman and a graduate student of hers discovered a different peptide that was distributed throughout the central nervous system, gastrointestinal tract, and immune system, but had yet to be identified. They decided to name their discovery “neurotensin”.
=== Incomplete conversion === Bisulfite sequencing relies on the conversion of every single unmethylated cytosine residue to uracil. If conversion is incomplete, the subsequent analysis will incorrectly interpret the unconverted unmethylated cytosines as methylated cytosines, resulting in false positive results for methylation. Only cytosines in single-stranded DNA are susceptible to attack by bisulfite, therefore denaturation of the DNA undergoing analysis is critical. It is important to ensure that reaction parameters such as temperature and salt concentration are suitable to maintain the DNA in a single-stranded conformation and allow for complete conversion. Embedding the DNA in agarose gel has been reported to improve the rate of conversion by keeping strands of DNA physically separate. Incomplete conversion rates can be estimated and adjusted-for after sequencing by including an internal control in the sequencing library, such as lambda phage DNA (which is known to be unmethylated) or by aligning bisulfite sequencing reads to a known unmethylated region in the organism, such as the chloroplast genome.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.